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2012.11.0Abstract Introduction: This study aimed to report the characteristics, prognostic factors and
treatment outcome of 223 patients with glioblastoma multiforme (GBM).
Subjects and method: This retrospective study was carried out by reviewing the medical records of
223 adult patients diagnosed at a tertiary academic hospital between 1990 and 2008. Patients’ follow
up ranged from 1 to 69 months (median 11 months). Surgery was attempted in all patients in whom
complete resection in 15 patients (7%), subtotal resection in 77 patients (34%), partial resection in
73 patients (33%) and biopsy alone in 58 patients (26%) were done. In addition, we performed a
literature review of PubMed to ﬁnd out and analyze major related series. In all, we collected and
analyzed the data of 33 major series including more than 11,000 patients with GBM.
Results: There were 141 men and 82 women. The median progression free- and overall survival
were 6 (95% CI = 5.711–8.289) and 11 (95% CI = 9.304–12.696) months respectively. In univar-
iate analysis for overall survival, age (P= 0.003), tumor size (P< 0.013), performance status
(P< 0.001), the extent of surgical resection (P= 0.009), dose of radiation (P< 0.001), and adju-
vant chemotherapy (P< 0.001) were prognostic factors. However, in multivariate analysis, onlyartment of Radiation Oncol-
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22 N. Ahmadloo et al.radiation dose, extent of surgical resection, and adjuvant chemotherapy were independent prognos-
tic factors for overall survival.
Conclusion: The prognosis of adult patients with GBM remains poor; however, complete surgical
resection and adjuvant treatments improve progression-free and overall survival.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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Glioblastoma multiforme (GBM) is the most common malig-
nant brain tumor in adults and accounts for 17% of intracra-
nial tumors [1]. Overall survival in GBM is usually less than
12 months and long-term survival is rare. Currently, safe opti-
mal surgical resection followed by adjuvant radiotherapy and
chemotherapy is considered as standard treatment approach
for patients with GBM. However, despite advances in the last
3 decades, outcome remains poor and long-term survival is
exceptional [2]. A ray of hope was temozolomide, a chemother-
apeutic agent that was introduced into the clinic in the 21st cen-
tury. It is simply used, well tolerated and clearly improved
survival. By progressive increase in temozolomide use, a mod-
est, but meaningful, survival improvement is observed [2,3]. A
new horizon is targeted therapy, particularly bevacizumab, a
recombinant humanized anti-vascular endothelial growth fac-
tor (VEGF) monoclonal antibody. It is the ﬁrst antiangiogenic
agent that has been clinically proven in the treatment of human
cancer. Investigation in this regard is continuing; however, re-
sults are not translated into clinical application so far [2,3].
The aim of this retrospective study was to deﬁne the character-
istics, prognostic factors and treatment outcomes of 223 adult
patients with GBM treated and followed-up in a single institu-
tion over a 19-year period and to perform a literature review.
Material and method
This retrospective study was carried out at a tertiary academic
hospital. We analyzed the characteristics, prognostic factors
and survival of adult patients (agedP 20 years) with histolog-
ically proven glioblastoma GBM who were treated and fol-
lowed-up between January 1990 and December 2008 at the
Shiraz University of Medical Sciences. In addition, to ﬁnd
out and analyze the major related series, a literature review of
PubMed was performed. In all, we collected the data of 33 ma-
jor series including more than 11,000 patients with GBM.
Patients’ evaluation
All patients were pathologically-proven newly diagnosedGBM.
In all, 223 patients were eligible to enter the study. Preoperative
performance status was deﬁned according to the Eastern Coop-
erative Oncology Group (ECOG). A preoperative and postop-
erative computed tomography (CT) scan and/or magnetic
resonance imaging (MRI) study was performed for all patients.
Surgery
Surgery was attempted in all patients in whom complete resec-
tion (deﬁned as resection of more than 98% of the tumor) in 15
patients (7%), subtotal resection (deﬁned as resection of morethan 50% of the tumor but less than complete resection) in 77
patients (34%), partial resection (any debulking surgical resec-
tion less than subtotal resection but more than open or stereo-
tactic biopsy) in 73 patients (33%) and biopsy alone in 58
patients (26%) were done. Preoperative and postoperative
imaging studies including computed tomography (CT) scan
and/or magnetic resonance imaging (MRI) were performed
for all patients. The extent of surgical resection and the size
of postoperative residual disease were deﬁned based on the
imaging ﬁndings and operative note.
Radiotherapy
Different external beam radiotherapy machines (megavoltage
telecobalt units or linear accelerator), radiation dose and tech-
niques had been used. Before 2000, the patients were initially
treated with 40 Gy whole brain conventional (daily fraction of
1.8–2 Gy, and ﬁve fractions per week) radiotherapy which
was continued to the primary tumor, using reduced size ﬁelds,
up to 54 Gy. Since 2000, involved ﬁeld radiotherapywith amed-
ian dose of 54 (range 40–60) Gy was considered for all patients
who were treated with a curative intent. Patients with poor gen-
eral condition were treated with palliative intent and only re-
ceived 30 Gy in 10 fractions. Patients with signiﬁcant tumor-
related or postsurgical complications such as severe anorexia,
nausea, vomiting (due to persistent increased intracranial cra-
nial pressure) weight loss, dysphagia and respiratory distress
(due to midbrain and brain stem involvement) and decreased le-
vel of consciousness could not complete their radiotherapy
plan. In addition, all patients received corticosteroids concur-
rently with radiotherapy and 9 patients received concurrent che-
moradiation with temozolomide. Five patients expired before
starting radiotherapy and 19 cases expired during the course
of radiotherapy and could not complete their radiotherapy.
Chemotherapy
Since 1998, adjuvant nitrosourea-based chemotherapy was con-
sidered for eligible patients with acceptable performance status
and without signiﬁcant comorbidity. One hundred and two pa-
tients received a median of 4 (range 1–6) cycles of nitrosourea-
based chemotherapy consisting of procarbazine, lomustine, and
vincristine (PCV regimen). Only 21 patients received adjuvant
temozolomide. Temozolomide was administered concurrently
with radiotherapy with a dose of 75 mg/m2 daily throughout the
radiation course followed by 4–6 cycles of adjuvant temozolomide
with a dose of 150–200 mg/m2 daily for 5 days, every 4 weeks.
Deﬁnition of survival
Date of surgery was considered as the time of diagnosis. Pro-
gression free survival was calculated from the date of surgery
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other sites of the brain. Overall survival was calculated from
the date of surgery to date of death due to any cause.
Statistics
Clinical and pathological variables were analyzed using the
SPSS for Windows version 17 statistical software (SPSS,
Chicago, IL). Categorical variables of patient demographics
(such as sex and performance status, categorized age), tumor
characteristics (such as location, laterality, and categorized
tumor size) and treatment modalities (such as type of surgery,
radiotherapy techniques, and type of chemotherapy) were
compared by using chi-square tests and for continuous vari-
ables such as patients’ age, radiation dose and tumor size Stu-
dent’s t tests were used. Proportions were compared with
Fisher’s exact test for unordered or ordered categorical vari-
ables. Patients who lost to follow-up were taken into accountTable 1 Univariate analysis of prognostic factors for progression f
Prognostic factors (patients No.) One-year PFS (%) Median
Age
650 years (91) 25.7 9
>50 years (132) 20.1 5
Sex
Male (141) 23.4 5
Female (82) 20.9 6
Primary site
Frontal (72) 17.7 6
Temporoparietal (109) 24.3 6
Occipital (27) 20.9 5
Others location (15) 29.2 9
Lateralization
Right (118) 20.1 5
Left (105) 23.9 6
Tumor size
<5 cm (89) 29.3 7
P5 cm (134) 18.1 6
Type of surgery
Partial or biopsy (131) 15.3 5
Subtotal resection (77) 27.2 7
Total resection (15) 57.1 12
Chemotherapy
Nitrosourea-based (102) 34.9 10
Temozolomide (21) 54.5 13
No chemotherapy (110) 5.8 4
Radiation dose
Incomplete or palliative dose (31) 6.2 3
>40 Gy and < 54 Gy (124) 26.9 9
P 54 Gy and 6 60 Gy (68) 21.7 7
Radiation technique
Whole brainﬁ involved ﬁeld (99) 15.7 5
Involved ﬁeld (114) 31.9 6
Performance status (ECOG)
0 or 1 (108) 25.9 9
2 (84) 24.0 7
3 or 4 (31) 6.2 4
PFS, progression free survival; ECOG, eastern cooperative oncology groin the survival analysis, which takes the last follow-up tumor
status for the calculation. Univariate analysis for progression
free survival and overall survival rates were performed using
the Kaplan–Meier method and prognostic factors were com-
pared using the log-rank test. Multiple-covariate analysis was
performed using the stepwise regression hazards regression
model. The hazard ratio for death (HR), with the 95% conﬁ-
dence interval (CI), was calculated for the variable groups.
The stratiﬁed log-rank test was used to compare treatment re-
sults in each variable group. A P value of 0.05 or less was con-
sidered to be statistically signiﬁcant.
Results
Patients’ age and sex
There were 82 women and 141 men ranging in age from 20 to
75 years, with a median age at diagnosis of 53 years. The peakree survival in 223 patients with glioblastoma multiforme.
PFS (month) P value Hazard ratio (HR) 95% CI
0.003 1.504 1.121–2.018
0.468 1.109 0.824–1.477
1.488 0.783–2.825
1.229 0.657–2.299
0.444 1.317 0.931–1.321
0.342 1.128 0.849–1.497
0.013 1.402 1.045–1.880
2.009 1.126–3.585
0.009 1.501 0.824–2.732
1.651 1.417–1.924
<0.001 1.280 1.146–1.430
4.537 2.814–7.316
<0.001 0.899 0.654–1.235
0.064 1.308 0.956–1.790
1.805 0.799–1.472
<0.001 5.040 3.193–7.955
up; HR, hazard ratio.
Figure 1 Kaplan–Meier survival curves of overall survival
categorized according to the patients’ age (P= 0.026).
Figure 3 Kaplan–Meier survival curves of overall survival
categorized according to the type of surgery (P= 0.037).
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sexes. One hundred and thirty-two patients were more than
50 years old at presentation and 91 patients were less than or
equal to 50 years old. The mean female patients’ age (48.4 ±
13.22 vs. 52.6 ± 13.44, P= 0.025, CI = 0.534–7.849), radia-
tion dose (53.2 ± 8.59 vs. 53.2 ± 8.31, P= 0.555, CI =
0.466–0.866), and tumor size (6.2 ± 2.30 vs. 6.2 ± 2.50,
P= 0.965, CI: 2.355–2.252) were not signiﬁcantly different
compared with those of male patients. In addition, there was
no signiﬁcant difference between female and male patients
according to the performance status (P= 0.394, CI = 0.384–
0.403), type of surgery (P= 0.874, 0868–0.881) and chemo-
therapy regimen (P= 0.115, CI = 0.113–0.126).
Treatment outcome and survival
After a median follow-up of 11 (range 1–69) months for sur-
viving patients, 4 patients were alive and without disease, eight
were alive with disease, 184 had died due to disease and 27 lostFigure 2 Kaplan–Meier survival curves of overall survival
categorized according to the patients’ performance status
(P< 0.001).
Figure 4 Kaplan–Meier survival curves of overall survival
categorized according to the type of chemotherapy (P< 0.001).their follow-up. The last follow-up tumor status was consid-
ered for patients who lost to follow-up and their data were
incorporated to the study population for calculation. These
patients were lost to follow-up during the course of RT (6
cases) or few weeks after that (21 cases). The median follow-
up for these cases was 2 (range 1–4) months. Almost all
recurrences occurred within radiation ﬁelds. The majority of
recurrences were within 2 cm of the margin of the initial tumor
bed. The median progression free- and overall survival were 6
(95% CI = 5.711–8.289) and 11 (95% CI = 9.304–12.696)
months respectively for all patients. The one-, 2- and 3-year
overall survival rates were 45.9%, 7.7% and 3.1% respectively.
The 4-month progression free survival for patients who lost to
follow-up was 52.5%.
Prognostic factors
All potential prognostic variables were analyzed to establish
their effect on progression free- and overall survival rates.
Table 2 Univariate analysis of prognostic factors for overall survival in 223 patients with glioblastoma multiforme.
Prognostic factors (Patients No.) One-year OS (%) Median OS (month) P value Hazard ratio (HR) 95% CI
Age
650 years (91) 59.2 12
>50 years (132) 36.9 9 0.001 1.542 1.149–2.070
Sex
Male (141) 44.1 9
Female (82) 49.9 11 0.400 1.121 0.838–1.500
Primary site
Frontal (72) 42.0 10
Temporoparietal (109) 47.8 12 1.367 0.720–2.596
Occipital (27) 40.1 7 1.113 0595–2.083
Other locations (15) 55.4 12 0.504 1.202 0.590–2.448
Lateralization
Right (118) 40.0 7
Left (105) 53.1 12 0.308 1.144 0.862–1.519
Tumor size
<5 cm (89) 56.6 12
P5 cm (134) 39.9 9 0.015 1.394 1.040–1.869
Type of surgery
Partial or biopsy (131) 38.1 7
Subtotal resection (77) 55.3 12 2.011 1.129–3.858
Total resection (15) 71.4 15 0.010 1.515 0.833–2.756
Chemotherapy
Nitrosourea-based (102) 74.9 13
Temozolomide (21) 81.8 16 0.845 0.450–1.587
No chemotherapy (110) 16.6 6 <0.001 2.860 2.108–3.880
Radiation dose
Incomplete or palliative dose (31) 3.8 5
>40 Gy and <54 Gy (124) 55.9 12 4.885 3.032–7.869
P54 Gy and 660 Gy (68) 47.7 11 <0.001 0.916 0.667–1.259
Radiation technique
Whole brainﬁ involved ﬁeld (99) 40.2 9
Involved ﬁeld (114) 51.1 10 0.103 1.268 0.927–1.734
Performance status (ECOG)
0 or 1 (108) 50.4 12
2 (84) 56.1 12 1.072 0.789–1.456
3 or 4 (31) 3.8 5 <0.001 5.332 3.379–8.415
OS, overall survival; ECOG, eastern cooperative oncology group; HR, hazard ratio.
Table 3 The multivariate stepwise regression hazards model analysis of prognostic factors for progression free survival in 223 patients
with glioblastoma multiforme.
Prognostic factors (Patients No.) P value Hazard ratio (HR) 95% CI
Radiation dose
Incomplete or palliative dose (31)
>40 Gy and <54 Gy (124)
P54 Gy and 660 Gy (68) <0.001 0.960 0.962–0.979
Extent of surgical resection
Biopsy (131)
Incomplete resection (77)
Complete resection (15) 0.003 0.690 0.543–0.878
Chemotherapy
Nitrosourea-based (102)
Temozolomide (21)
No chemotherapy (110) <0.001 1.622 1.382–1.904
ECOG, eastern cooperative oncology group; HR, hazard ratio.
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Table 4 Multivariate stepwise regression hazards model analysis of prognostic factors for overall survival in 223 patients with
glioblastoma multiforme.
Prognostic factors (Patients No.) P value Hazard ratio (HR) 95% CI
Radiation dose
Incomplete or palliative dose (31)
>40 Gy and <54 Gy (124)
P54 Gy and 660 Gy (68) <0.001 0.957 0.939–0.976
Extent of surgical resection
Biopsy (131)
Incomplete resection (77)
Complete resection (15) 0.002 0.690 0.543–0.877
Chemotherapy
Nitrosourea-based (102)
Temozolomide (21)
No chemotherapy (110) <0.001 1.652 1.407–1.940
ECOG, eastern cooperative oncology group; HR, hazard ratio.
26 N. Ahmadloo et al.On univariate analysis of prognostic factors for progression
free survival, age (P= 0.001), tumor size (P= 0.018), perfor-
mance status (P< 0.001), the extent of surgical resection
(P= 0.010), dose of radiation (P< 0.001), and adjuvant che-
motherapy (P< 0.001) were prognostic factors. In addition,
we found a signiﬁcant improvement for progression free sur-
vival (P= 0.021) and overall survival (P= 0.010) for patients
who were treated after 2005 compared to those treated before
2005. However, sex, tumor location and radiotherapy tech-
niques were found not to be prognostic factors for progression
free survival (Table 1).
Similarly, on univariate analysis of prognostic factors for
overall survival, age (P= 0.003), tumor size (P< 0.013), per-
formance status (P< 0.001), the extent of surgical resection
(P= 0.009), dose of radiation (P< 0.001), and adjuvant che-
motherapy (P< 0.001) were prognostic factors. (Figs. 1–4)
However, sex, tumor location and radiotherapy techniques
were found not to be prognostic factors for progression free
survival (Table 2).
On multivariate stepwise regression hazards model analysis
of prognostic factors for progression free survival, adjuvant
chemotherapy [HR= 1.622; 95% CI = 1.382–1.904; (P=
<0.001)], radiation dose [HR= 0.960; 95% CI = 0.962–
0.979; (P=<0.001)], and the extent of surgical resection
[HR= 0.690; 95% CI = 0.543–0.878; (P= 0.003)] were inde-
pendent prognostic factors for progression free survival (Table
3).
Likewise, multivariate stepwise regression hazards model
analysis of prognostic factors for overall survival revealed that
adjuvant chemotherapy [HR = 1.652; 95% CI = 1.407–1.940;
(P=<0.001)], radiation dose [HR = 0.957; 95%CI = 0.939–
0976; (P=<0.001)], and the extent of surgical resection
[HR= 0.690; 95% CI = 0.543–0.877; (P= 0.002)] had re-
tained statistical signiﬁcance for overall survival (Table 4).
Discussion
Glioblastoma multiforme is the most aggressive primary cen-
tral nervous system (CNS) neoplasm. The incidence of GBM
does not depend on geographic or ethnical factors. These neo-
plasms usually occur in the sixth and seventh decades of life
[1,4]. In the present study, the median age of our patientswas 53 years, which was consistent with the results of the liter-
ature review in which the average median age of 7726 patients
in the reported series was 62 years [5–31]. (Table 5).
In almost all reported series in the literature review, men
represent a higher proportion of GBM sufferers than women,
with a mean male/female ratio of 1.4 (range from 1.0 to 1.9) in
8 studies including 4933 patients [10,12,18,22–25,31] (Table 5).
In the present study this ratio was 1.7 which was consistent
with the reported series.
Glioblastoma multiforme are diffusely inﬁltrative tumors;
consequently, surgical curative resection is rarely possible for
this neoplasm [1]. Optimal safe resection is an essential goal
in the initial management of patients with GBM, and the ex-
tent of surgical resection must be balanced against the risk
of neurologic dysfunction. A variety of preoperative neuroim-
aging and intraoperative mapping and neuromonitoring have
been incorporated into the patient management to achieve
these goals [2,32,33]. At present most neurosurgical operating
rooms are specially designed and equipped with computerized
tomography (CT) or magnetic resonance imaging (MRI) scan-
ners to guide the real time resection. Currently, modern intra-
operative neurosurgical techniques are used to facilitate the
optimal tumor resection while minimizing normal brain dam-
age [32]. There is no consensus regarding the deﬁnition of com-
plete brain tumor resection in the literature. Many authors
used the terms of ‘‘complete’’ [8,24,34], ‘‘total’’ [11,35,36],
‘‘gross total’’ [5,26,37] or ‘‘more than 98% tumor’’ resection
[2,32] according to the postsurgical residual disease.
In the literature review, the mean rate of complete (total
gross) resection was 33% (range 10–63%) in 11 reports includ-
ing 3078 patients. In addition, the mean rate of biopsy alone
was 20% (range 1–56%) in 15 reports including 7836 patients
[8,12,16,23,24,28,34–41]. Fig. 5 represents the relative distribu-
tion of the extent of surgical resection among 3078 patients
with glioblastoma multiforme in 11 reported series in the liter-
ature [8,16,24,28,34–40].
In the present study, the rate of complete tumor resection
(deﬁned as resection of more than 98% of the tumor) was sig-
niﬁcantly lower (7% vs. 33%) than that of the mean value in
the reported series [8,16,24,28,34–40], and the rate of biopsy
alone was relatively higher (26% vs. 20%) than that of the
mean value in the reported series [12,16,17,23,36,38,40,41].
Figure 5 Relative distribution of the extent of surgical resection
among 3078 patients with glioblastoma multiforme in the litera-
ture. [8,16,24,28,34–40].
Table 5 Characteristics and treatment outcomes of 28 major reported series of glioblastoma multiforme.
Authors [Ref.] No. of
patients
Mean
age
M/F
ratio
Median OS
(month)
Median PFS
(month)
1-year
OS (%)
2-year
OS (%)
3-year
OS (%)
Caloglu [5] 78 – – 9.8 – – – –
Chaichana [6] 129 73 – 7.9 – – – –
Chaichana [7] 393 – – 11.9 – – – –
Ewelt [8] 103 70.8 – 5.1 3.2 – – –
Fazeny-Dorner [9] 357 – – 9.4 – – – –
Filippini [10] 676 58 1.6 13.6 6.0 57 16 7
Gamburg, [11] 114 – – 6 – – – –
Grossman [12] 219 55 1.2 11.1 – 44.5 – –
Hall [13] 21 38 – 8 – – – –
Helseth [14] 516 63.7 – 9.9 – – – –
Jeremic [15] 175 – – 14 – – – –
Lai [16] 1375 72 – 8.9 – – – –
Li [18] 116 – 1.9 16.9 9.1 – – –
Li [17] 192 53 – 15.7 – 62.5 25.5 –
Lin [19] 69 – – 12 – – – –
Ma [20] 205 – – 12 – 52 17 –
McGirt [21] 306 54 – 12.8 – – 20 10
Odrazka [22] 85 58 1 10.1 – 41 5 –
Paszat [23] 3279 61 1.44 7 – 29.4 11.1 7.4
Piroth [24] 110 61.4 1 8.7 4.8 28 5 –
Scoccianti [41] 1059 – – 9.5 – – 24.8 –
Scott [25] 206 75 1.2 4.5 – – – –
Shinoda [26] 82 – – 13 – 53.7 14.6 –
Shrieve [27] 78 – – 19.9 – 88.5 35.9 –
Stark [28] 267 61 1.2 7 – – – –
Tait [29] 625 – – 6.3 – – – –
Tramacere [30] 75 – – 14.7 – 69.3 38.4 14.7
Wasserfallen [31] 46 52 1.5 15.8 – – – –
Present study 223 51 1.72 11 6 45.9 7.7 3.1
Total 11,179 62 1.43 9.2 5.9 41.3 15.7 7.7
M/F, male/female; PFS, Progression free survival; OS, overall survival.
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scan and magnetic resonance spectroscopy (MRS)] and intra-
operative mapping and neuromonitoring particularly before
2005 were our limitation resource causing our lower rate of
complete resection compared to most reported series. It may
also be due to the different deﬁnition of the extent of surgical
resection among the reported series.
Postoperative adjuvant radiotherapy is a principal element
in the treatment of patients with GBM [2]. External beam
radiotherapy is usually recommended to start within 2–4 weeks
following surgical resection or biopsy. A total dose of 60 Gy is
often delivered using involved portals and conventionalfractionation (daily fractions of 2 Gy, ﬁve fractions per day)
[2,16,36]. In the present study, the vast majority (86%) of pa-
tients were treated with a curative intent, however; only 31%
received the optimal or acceptable radiation dose. It was mainly
due to poor patients’ compliance, poor performance status, and
our limited resource before 2000. Before 2000, we had no linear
accelerator and patients were treated with cobalt 60 telether-
apy. Therefore, for avoiding the toxicities of optimal radiation
dose (60 Gy), most patients received up to 54 Gy.
Adjuvant chemotherapy plays an important role in the
management of patients with GBM [2,10]. Before 1999, nitro-
sourea-based combinations were the most commonly used che-
motherapeutic agents in GBM, among which carmustine and
lomustine were the most active agents. However, by adding
these agents to combined surgery and postoperative radiother-
apy, no signiﬁcant improvements in terms of response rates
and overall survival were observed [2,42]. Since 1999 and by
introducing temozolomide a modest improvement in median
survival was seen. At present, concurrent chemoradiation fol-
lowed by sequential adjuvant temozolomide is recommended
for patients with GBM [2,9,43,44].
In the present study, chemotherapy was considered for 108
(48.5%) eligible patients with acceptable performance status
and without signiﬁcant comorbidity since 1998. However,
due to the lack of medical insurance coverage for this drug, pa-
tients’ low economic status and other limited resources, most
28 N. Ahmadloo et al.cases did not receive temozolomide. Therefore, only 21 (9.5%)
patients received adjuvant temozolomide.
Glioblastoma multiforme is a highly aggressive tumor,
median survival is usually less than 12 months and long-term
survival is exceptional [23,45]. In the present study, the median
progression-free survival was 6 months which was in agree-
ment with 5.9 months for 1201 patients in the literature
[8,10,18,24]. Correspondingly, the median overall survival of
our patients was 11 months which was comparable with
9.2 months for 11,152 patients in the literature [5–31,41].
1-, 2- and 3-year overall response rates were 41.5 (in 5197
patients) [10,12,17,20,22–24,26,27,30], 15.6% (in 6343 pa-
tients) [10,17,20–23,26,27,30,41], and 7.7% (in 4532 patients)
[10,21,23,30] respectively in the literature. In the present study,
these rates were 45.9%, 7.7% and 3.1% respectively, among
which 2- and 3-year overall response rates were lower than that
in the literature.
In almost all reported series in the literature, we found
young age, good performance status and safe optimal resection
to be the well-known good prognostic factors in patients with
GBM [2,5,7,8,10,11,14–18,22,24–31,38,40,41,46,47]. In the
present study, we found radiation dose, extent of surgical
resection, and adjuvant chemotherapy to be independent prog-
nostic factors for overall survival. These results were consistent
with the results of other reported series in the literature in
which adjuvant radiotherapy particularly with higher doses
(P60 Gy); and adjuvant chemotherapy particularly concur-
rent chemoradiation with temozolomide were favorable prog-
nostic factors for overall survival [2–5,8–10,12–18,20,22–
24,27–29,31,33,36–41,47–54].
Mutations of tumor suppressor genes, particularly p53 and
ampliﬁcations of oncogenes especially EGFR gene ampliﬁca-
tion play an important role in the pathogenesis and progres-
sion of GBM. These molecular genetic alterations are
important targets for use in the early detection of these neo-
plasms. Consequently, molecular analysis and proﬁling ap-
proach using immunohistochemistry would provide novel
diagnostic and prognostic perceptions in the biology of
GBM [55,56]. In this series, there were no data regarding
molecular markers, and these markers are not routinely
checked in our patients with GBM.Conclusion
According to the ﬁndings of the present study and review of
the literature, GBM is a highly violent tumor; tends to have
early relapse and short-term survival. Multimodality therapy
including safe optimal surgical resection combined by adjuvant
radiotherapy or concurrent chemoradiation and sequential
chemotherapy is recommended for all patients with this fatal
neoplasm. Despite modest improvement in the overall survival
of patients with GBM in the recent decade, the outcome re-
mains poor. Therefore, the need for more effective novel treat-
ments in this neoplasm is urgently needed. This study
emphasizes that the current standard of care is not feasible
everywhere in the world largely due to cost. Research into eco-
nomically viable treatments is needed. In addition, our results
emphasize that the current standard of care is not that great,
since survival is still similar even when most patients do not
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